Citadel Advisors’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-199,269
| Closed | -$650K | – | 16246 |
|
|
2022
Q4 | $650K | Sell |
199,269
-421
| -0.2% | -$1.01K | ﹤0.01% | 7706 |
|
|
2022
Q3 | $587K | Sell |
199,690
-11,794
| -6% | -$40.3K | ﹤0.01% | 8117 |
|
|
2022
Q2 | $520K | Buy |
211,484
+11,701
| +6% | +$54.2K | ﹤0.01% | 8556 |
|
|
2022
Q1 | $1.61M | Buy |
199,783
+23,481
| +13% | +$240K | ﹤0.01% | 6568 |
|
|
2021
Q4 | $2.35M | Buy |
176,302
+123,498
| +234% | +$3.1M | ﹤0.01% | 5879 |
|
|
2021
Q3 | $2.3M | Buy |
52,804
+51,433
| +3,751% | +$2.22M | ﹤0.01% | 5996 |
|
|
2021
Q2 | $57K | Buy |
+1,371
| New | +$60.2K | ﹤0.01% | 13282 |
|
|
2021
Q1 | – | Sell |
-2,524
| Closed | -$147K | – | 13947 |
|
|
2020
Q4 | $248K | Buy |
2,524
+1,792
| +245% | +$157K | ﹤0.01% | 9413 |
|
|
2020
Q3 | $50K | Buy |
+732
| New | +$63.9K | ﹤0.01% | 9607 |
|
|
2020
Q2 | – | Sell |
-2,423
| Closed | -$288K | – | 10764 |
|
|
2020
Q1 | $215K | Buy |
2,423
+825
| +52% | +$98.3K | ﹤0.01% | 7897 |
|
|
2019
Q4 | $183K | Buy |
1,598
+346
| +28% | +$26K | ﹤0.01% | 8253 |
|
|
2019
Q3 | $77K | Sell |
1,252
-9,473
| -88% | -$758K | ﹤0.01% | 8588 |
|
|
2019
Q2 | $837K | Buy |
10,725
+8,823
| +464% | +$1M | ﹤0.01% | 5990 |
|
|
2019
Q1 | $256K | Sell |
1,902
-877
| -32% | -$92.1K | ﹤0.01% | 7847 |
|
|
2018
Q4 | $223K | Sell |
2,779
-3,339
| -55% | -$329K | ﹤0.01% | 7711 |
|
|
2018
Q3 | $643K | Buy |
6,118
+1,356
| +28% | +$129K | ﹤0.01% | 6296 |
|
|
2018
Q2 | $476K | Buy |
4,762
+1,078
| +29% | +$122K | ﹤0.01% | 6453 |
|
|
2018
Q1 | $464K | Sell |
3,684
-40,312
| -92% | -$6.29M | ﹤0.01% | 6004 |
|
|
2017
Q4 | $7.35M | Buy |
43,996
+19,962
| +83% | +$5.11M | ﹤0.01% | 2029 |
|
|
2017
Q3 | $7.57M | Sell |
24,034
-4,526
| -16% | -$1.43M | 0.01% | 1875 |
|
|
2017
Q2 | $8.48M | Buy |
28,560
+1,424
| +5% | +$381K | 0.01% | 1589 |
|
|
2017
Q1 | $6.27M | Buy |
+27,136
| New | +$4.69M | 0.01% | 1829 |
|
|
2016
Q1 | – | Sell |
-1,044
| Closed | -$160K | – | 8368 |
|
|
2015
Q4 | $160K | Buy |
1,044
+825
| +377% | +$124K | ﹤0.01% | 6111 |
|
|
2015
Q3 | $24K | Buy |
+219
| New | +$28.4K | ﹤0.01% | 8052 |
|
Other funds holding CALA
Citadel Advisors's CALA Position: Q1 2023 in Review
Citadel Advisors sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 199,269 shares — an estimated $650K sold.
Citadel Advisors first reported a position in CALA in Q3 2015 and held it in 24 quarters. The position peaked at $8.48M in Q2 2017. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- Citadel Advisors reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 199,269 Calithera Biosciences, Inc shares in Q1 2023, an estimated $650K.
- Citadel Advisors first reported a position in Calithera Biosciences, Inc in Q3 2015 and held it in 24 quarters.
- Citadel Advisors's Calithera Biosciences, Inc position peaked at $8.48M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.